Skip to main content
OpenTrials
Completed

NCT Number: NCT00526708

Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )

To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Seoul, Jongro-gu, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria
  • Over 18 years of age
  • Currently or previously diagnosed with hypertension and receiving medical care

Exclusion criteria

  • Patients already taking other hyperlipidemic agents
  • Patients who do not fulfil the indication criteria for statin therapy
  • Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)

Acronym: RUSH

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Sep 10, 2007
Registry last updated
Dec 1, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.